Chronische Berylliose

J. Müller-Quernheim; K. I. Gaede; A. Prasse; G. Zissel

doi:10.1055/s-2006-954984

Pneumologie, Table of Contents

Pneumologie 2007; 61(2): 109-116
DOI: 10.1055/s-2006-954984

Übersicht

Chronische Berylliose

Chronic BerylliosisJ. Müller-Quernheim¹ , K. I. Gaede² , A. Prasse¹ , G. Zissel¹

¹Abteilung für Pneumologie, Medizinische Klinik, Albert Ludwigs Universität Freiburg
²Medizinische Klinik, Forschungszentrum Borstel, Borstel

Abstract

Zusammenfassung

Die chronische Berylliose (CB) ist eine Berufserkrankung, die bei der Differenzialdiagnose granulomatöser Lungenerkrankungen berücksichtigt werden muss. Die Bundesrepublik Deutschland ist einer der größten Beryllium-Importeure mit weiter steigendem Verbrauch und daher muss mit einer zunehmenden Zahl an Erkrankungsfällen gerechnet werden. Da die CB eine perfekte Phänokopie der Sarkoidose ist, kann sie klinisch von ihr nicht differenziert werden. Daher kann davon ausgegangen werden, dass viele CB-Patienten in der Kohorte der Sarkoidosepatienten verborgen sind. Die Epidemiologie, Pathogenese, Diagnostik und Therapie der CB wird dargestellt.

Abstract

Chronic Berylliosis (CB) is an occupational disorder which needs to be considered in the diagnostic work-up of granulomatous pulmonary diseases. Germany imports increasing amounts of beryllium which causes increased occupational exposure and this fact suggests that CB is underdiagnosed. Since CB is a perfect phenocopy of sarcoidosis, it is assumed that many cases are hidden in the cohort of sarcoidosis patients. This review presents the epidemiology, pathogenesis, diagnostics, and therapy of CB.

Full Text

References

Literatur

1 Jones Williams W. Beryllium disease. In: James D (ed). Sarcoidosis and other granulomatous disorders. New York: Marcel Dekker 1994: 707-721
2 Meyer K. Beryllium and lung disease disease. Chest. 1994; 106 942-946
3 Schönherr S, Pevny H. Berylliumallergie. Arbeitsmed Sozialmed Präventivmed. 1985; 20 281-286
4 Rietschel R, Vowler J J. Fisher's contact dermatitis. 4th ed. Baltimore: Williams & Wilkens 1995
5 MacMahon B. The epidemiological evidence on the carcinogenicity of Beryllium in humans. J Occup Med. 1994; 36 15-24
6 Steenland K, Ward E. Lung cancer incidence among patients with Beryllium disease: A cohort mortality study. J Nat Cancer Inst. 1991; 83 1380-1385
7 Askling J, Grunewald J, Eklund A. et al . Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med. 1999; 160 1668-1672
8 Sanderson W T, Petersen M R, Ward E M. Estimating historical exposures of workers in a beryllium manufacturing plant. Am J Ind Med. 2001; 39 145-157
9 Sanderson W T, Ward E M, Steenland K. et al . Lung cancer case-control study of beryllium workers. Am J Ind Med. 2001; 39 133-144
10 Senatskommisssion zur Prüfung gesundheitsschädlicher Arbeitsstoffe der Deutschen Forschungsgemeinschaft .Beryllium und seine anorganischen Verbindungen. In: Greim H (ed). Gesundheitsschädliche Arbeitsstoffe Toxikologisch-arbeitsmedizinische Begründungen von MAK-Werten (Maximale Arbeitsplatzkonzentrationen). Weinheim: VCH Verlagsgesellschaft 2003: 37. Lieferung
11 Newman L S. Metals that cause sarcoidosis. Semin Respir Infect. 1998; 13 212-220
12 Newman L S. Beryllium disease and sarcoidosis: Clinical and laboratory links. Sarcoidosis. 1995; 12 7-19
13 Newman L S, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: Identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis. 1992; 145 1212-1214
14 Middleton D C. Chronic beryllium disease: uncommon disease, less common diagnosis. Environ Health Perspect. 1998; 106 765-767
15 Rossman M D. Chronic beryllium disease: diagnosis and management. Environ Health Perspect. 1996; 104 Suppl 5 945-947
16 Müller-Quernheim J, Gaede K I, Fireman E. et al . Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J. 2006; 27 1190-1195
17 Infante P F, Newman L S. Beryllium exposure and chronic beryllium disease. Lancet. 2004; 363 415-416
18 Henneberger P K, Goe S K, Miller W E. et al . Prevention of beryllium sensitization and chronic beryllium disease. J Occup Environ Hyg. 2006; 3 D42-43
19 Rossman M D, Kreider M E. Is chronic beryllium disease sarcoidosis of known etiology?. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20 104-109
20 Kreiss K, Mroz M M, Newman L S. et al . Machining risk of beryllium disease and sensitization with median exposures below 2 micrograms/m^3. . Am J Ind Med. 1996; 30 16-25
21 Hooper W F. Acute beryllium lung disease. N C Med J. 1981; 42 551-553
22 Kriebel D, Sprince N L, Eisen E A. et al . Pulmonary function in beryllium workers: assessment of exposure. Br J Ind Med. 1988; 45 83-92
23 Drexler H, Greim H. The MAK-Collection Part II: BAT Value Documentations, Volume 4. Weinheim: Wiley-VCH 2005
24 Willis H H, Florig H K. Potential exposures and risks from beryllium-containing products. Risk Anal. 2002; 22 1019-1033
25 Maier L, Martyny J, Mroz M. et al . Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease. Chest. 2002; 121 81S
26 Henneberger P K, Cumro D, Deubner D D. et al . Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health. 2001; 74 167-176
27 Kreiss K, Wassermann S, Mroz M M. et al . Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med. 1993; 35 267-274
28 Newman L S, Mroz M M, Balkissoon R. et al . Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med. 2005; 171 54-60
29 Newman L S, Mroz M M, Maier L A. et al . Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med. 2001; 43 231-237
30 Entzian P, Pawelek W, Lindner B. et al . Grenzen des Berylliumnachweises mit der Laser-Mikrobereichs-Massenspektrometrie [Limits of beryllium detection with laser microprobe mass spectrometry (LAMMS)]. Pneumologie. 1998; 52 674-679
31 Sumino K, Hayakawa K, Shibata T. et al . Heavy metals in normal Japanese tissues. Amounts of 15 heavy metals in 30 subjects. Arch Environ Health. 1975; 30 487-494
32 Wegner R, Heinrich-Ramm R, Nowak D. et al . Lung function, biological monitoring, and biological effect monitoring of gemstone cutters exposed to beryls. Occup Environ Med. 2000; 57 133-139
33 Verma D K, Ritchie A C, Shaw M L. Measurement of beryllium in lung tissue of a chronic beryllium disease case and cases with sarcoidosis. Occup Med (Lond). 2003; 53 223-227
34 Cullen M R, Kominsky J R, Rossman M D. et al . Chronic beryllium disease in a precious metal refinery. Clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am Rev Respir Dis. 1987; 135 201-208
35 Bartell S M, Ponce R A, Takaro T K. et al . Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk Anal. 2000; 20 87-99
36 Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J. 1998; 12 716-738
37 Bost T W, Riches D WH, Schumacher B. et al . Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin-1β. Am J Respir Cell Mol Biol. 1994; 10 506-513
38 Gaede K I, Mamat U, Schlaak M. et al . Analysis of differentially regulated mRNAs in peripheral blood monocytes of berylliosis patients after in vitro stimulation. J Mol Med. 2000; 78 293-299
39 Richeldi L, Sorrentino R, Saltini C. HLA-DPB 1 glutamate 69: a genetic marker of beryllium disease. Science. 1993; 262 242-244
40 Richeldi L, Kreiss K, Mroz M M. et al . Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997; 32 337-340
41 Wang Z, White P S, Petrovic M. et al . Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999; 163 1647-1653
42 Rossman M D, Stubbs J, Lee C W. et al . Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med. 2002; 165 788-794
43 Saltini C, Richeldi L, Losi M. et al . Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001; 18 677-684
44 Maier L A, Sawyer R T, Bauer R A. et al . High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med. 2001; 164 1192-1199
45 Gaede K I, Amicosante M, Schurmann M. et al . Function associated transforming growth factor-β gene polymorphism in chronic beryllium disease. J Mol Med. 2005; 83 397-405
46 Maier L A, Raynolds M V, Young D A. et al . Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med. 1999; 159 1342-1350
47 Newman L S, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis. 1992; 146 39-42
48 Weston A, Ensey J, Kreiss K. et al . Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease. Am J Ind Med. 2002; 41 457-465
49 Maier L A. Genetic and exposure risks for chronic beryllium disease. Clin Chest Med. 2002; 23 827-839
50 Saltini C, Amicosante M, Franchi A. et al . Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J. 1998; 12 1463-1475
51 McCunney R J. Genetic testing: ethical implications in the workplace. Occup Med. 2002; 17 665-672
52 Amicosante M, Sanarico N, Berretta F. et al . Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol. 2001; 62 686-693
53 Lombardi G, Germain C, Uren J. et al . HLA-DP allele-specific T cell responses to beryllium account for DP- associated susceptibility to chronic beryllium disease. J Immunol. 2001; 166 3549-3555
54 Fontenot A P, Torres M, Marshall W H. et al . Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA. 2000; 97 12 717-12 722
55 Saltini C, Winestock K, Kirby M. et al . Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989; 320 1103-1109
56 Saltini C, Kirby M, Trapnell B C. et al . Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med. 1990; 171 1123-1140
57 Fontenot A P, Canavera S J, Gharavi L. et al . Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest. 2002; 110 1473-1482
58 Fontenot A P, Falta M T, Freed B M. et al . Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol. 1999; 163 1019-1026
59 Amicosante M, Berretta F, Franchi A. et al . HLA-DP-unrestricted TNF-α release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J. 2002; 20 1174-1178
60 Tinkle S S, Schwitters P W, Newman L S. Cytokine production by bronchoalveolar lavage cells in chronic beryllium disease. Environ Health Perspect. 1996; 104 Suppl 5 969-971
61 Ziegenhagen M W, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003; 253 18-30
62 Middleton D C, Lewin M D, Kowalski P J. et al . The BeLPT: algorithms and implications. Am J Ind Med. 2006; 49 36-44
63 Stange A W, Furman F J, Hilmas D E. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance. Am J Ind Med. 2004; 46 453-462
64 Taylor T P, Ding M, Ehler D S. et al . Beryllium in the environment: a review. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003; 38 439-469
65 Vilaplana J, Romaguera C, Grimalt F. Occupational and non-occupational allergic contact dermatitis from beryllium. Contact Dermatitis. 1992; 26 295-298
66 Bobka C A, Stewart L A, Engelken G J. et al . Comparison of in vivo and in vitro measures of beryllium sensitization. J Occup Environ Med. 1997; 39 540-547
67 Schreiber J, Zissel G, Greinert U. et al . Diagnostik der chronischen Berylliosis. Pneumologie. 1999; 53 193-198
68 Curtis G. The diagnosis of Beryllium disease, with special reference to the patch test. Arch Indust Health. 1959; 19 150-153
69 Newman L S, Kreiss K, King T E. et al . Pathological and immunological alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis. 1989; 139 1479-1486
70 Lundgren R A, Maier L A, Rose C S. et al . Indirect and direct gas exchange at maximum exercise in beryllium sensitization and disease. Chest. 2001; 120 1702-1708
71 Daniloff E M, Lynch D A, Bartelson B B. et al . Observer variation and relationship of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med. 1997; 155 2047-2056
72 Newman L S, Buschman D L, Newell Jr J D. et al . Beryllium disease: assessment with CT. Radiology. 1994; 190 835-840
73 Stange A W, Furman F J, Hilmas D E. Rocky Flats Beryllium Health Surveillance. Environ Health Perspect. 1996; 104S 981-986
74 Kreiss K, Mroz M M, Zhen B. et al . Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med. 1997; 54 605-612
75 Pappas G P, Newman L S. Early pulmonary physiologic abnormalities in Beryllium disease. Am Rev Respir Dis. 1993; 148 661-666
76 Kreiss K, Mroz M M, Zhen B. et al . Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993; 148 985-991
77 Schepers G. The mineral content of the lung in chronic berylliosis. J Dis Chest. 1962; 42 600-607
78 Kent D C, Houk V N, Elliott R C. et al . The definitive evaluation of sarcoidosis. Am Rev Respir Dis. 1970; 101 721-727
79 Grunewald J, Eklund A. [It's difficult to differentiate between sarcoidosis and berylliosis!]. Lakartidningen. 2000; 97 5915-5918
80 Fireman E, Kramer M R, Kaufman N. et al . Beryllium disease: first case reported in Israel. Isr Med Assoc J. 2001; 3 224-225
81 Bargon J, Rust M, Kronenberger H. et al . Klinik und Diagnostik der chronischen Berylliose - Eine Kasuistik. Pneumologie. 1990; 44 Suppl 1 320-321
82 Müller-Quernheim J, Zissel G, Schopf R. et al . Differenzialdiagnose Berylliose/Sarkoidose bei einem Zahntechniker. Dtsch Med Wochenschr. 1996; 121 1462-1466
83 Sprince N L, Kanarek D J, Weber A L. et al . Reversible respiratory disease in beryllium workers. Am Rev Respir Dis. 1978; 117 1011-1017
84 Müller-Quernheim J. Die Indikation zur Kortikosteroid-Therapie der Sarkoidose und die Bewertung ihrer Resultate. Pneumologie. 2000; 54 284-286
85 Müller-Quernheim J. Sarcoidosis, part II: Clinical manifestations, staging, and therapy. Respir Med. 1998; 92 140-139
86 Müller-Quernheim J, Dalhoff K, Schnabel A. Immunsuppressive Therapie bei interstitiellen Lungenerkrankungen und immunologisch vermittelten Pneumonitiden. Internist (Berl). 1997; 38 553-561
87 Sood A, Beckett W S, Cullen M R. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest. 2004; 126 2000-2007
88 Nagaoka K, Yoshida T, Sakakibara H. et al . Significant improvement from chronic beryllium disease following corticosteroid pulse therapy. Ind Health. 2006; 44 296-301
89 Müller-Quernheim J, Kienast K, Held M. et al . Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999; 14 1117-1122
90 Lang L. Beryllium: A Chronic Problem. Environ Health Perspect. 1994; 102 526-531

Prof. Dr. J. Müller-Quernheim

Abteilung für Pneumologie, Medizinische Klinik, Uniklinikum Freiburg

Killianstraße 5

79106 Freiburg

Email: joachim.mueller-quernheim@uniklinik-freiburg.de